Brain Diseases, Metabolic: Clinical Trials

1,525 trials for Brain Diseases, Metabolic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

738 completed, 230 recruiting, 179 unknown, 121 terminated. 309 Phase 2, 259 Not applicable, 215 Phase 1, 170 Phase 3, 98 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2309Completed 166, Terminated 39, Recruiting 25, Active not recruiting 24, Withdrawn 19, Not yet recruiting 15, Unknown 15, Suspended 4, Enrolling by invitation 2
Not applicable259Completed 138, Unknown 40, Recruiting 35, Not yet recruiting 17, Terminated 14, Active not recruiting 8, Withdrawn 6, Enrolling by invitation 1
Phase 1215Completed 109, Recruiting 28, Terminated 25, Active not recruiting 18, Not yet recruiting 12, Withdrawn 11, Unknown 7, Suspended 3, Enrolling by invitation 2
Phase 3170Completed 103, Terminated 18, Recruiting 17, Active not recruiting 14, Unknown 8, Withdrawn 6, Not yet recruiting 3, Enrolling by invitation 1
Phase 498Completed 54, Unknown 18, Recruiting 8, Terminated 8, Active not recruiting 4, Withdrawn 4, Not yet recruiting 2
Early Phase 119Recruiting 5, Completed 4, Unknown 4, Active not recruiting 2, Not yet recruiting 2, Terminated 2

Follow Brain Diseases, Metabolic: new trials by email Literature Review of Brain Diseases, Metabolic trials Research Report on Brain Diseases, Metabolic

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
To Evaluate the Safety and Efficacy of GS1168 Injection in Adult Phenylketonuria
GS1168 injection - Phenylketonuria (PKU)
Early Phase 1Not yet recruitingGritgen Therapeutics Co., Ltd.92027-12-312026-09-10
IT and IV Lentiviral Gene Therapy for X-ALD
Intrathecal and intravenous LV gene therapy - X-linked Adrenoleukodystrophy
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute302027-06-012026-11-02
Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD
Lentiviral TYF-ARSA correction of patient's autologous HSCs - Metachromatic Leukodystrophy (MLD)
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute102027-06-012026-11-02
Direct Lentiviral Injection Gene Therapy for MLD
Intrathecal and intravenous LV gene therapy - Metachromatic Leukodystrophy (MLD)
Not applicableNot yet recruitingShenzhen Geno-Immune Medical Institute102027-05-312026-11-02
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Phase 1 / Phase 2Not yet recruitingGeorge Washington University242027-03-012026-10-05
A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home Infusion
Gaucher Disease
Not yet recruitingTakeda602027-01-312026-10-01
Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)
AZ-3102 - Gaucher Disease Type 3
Phase 2Not yet recruitingAzafaros B.V.202027-01-252026-11-12
Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis Clinical Trial
Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase - GM1 Gangliosidoses, GM1 Gangliosidosis, Type I
Phase 1Not yet recruitingTippi Mackenzie52027-01-012026-08-31
Outside the Cage (OTC) Robotic Esophagectomy
OTC MIE Esophagectomy - Esophageal Cancer
Phase 1Not yet recruitingCentre hospitalier de l'Université de Montréal (CHUM)312027-01-012026-03-18
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
GD2, PSMA and CD276 CAR-T cells - Neuroblastoma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute1002026-12-312026-10-30
The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)
Venglustat, Imiglucerase - Gaucher's Disease Type III
Phase 3Not yet recruitingSanofi182026-12-112026-11-10
Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders
AZ-3102 - Niemann-Pick Disease Type C, GM2 Gangliosidosis
Phase 2 / Phase 3Not yet recruitingAzafaros B.V.2182026-12-102026-10-21
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)
PLX-200 - Lysosomal Storage Disorders, Sandhoff Disease
Phase 2Not yet recruitingPolaryx Therapeutics, Inc.242026-12-012026-07-31
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
Lucerastat - Fabry Disease
Phase 3RecruitingIdorsia Pharmaceuticals Ltd.162026-12-012026-11-03
Daridorexant for Sleep Disturbance in Adults With Liver Cirrhosis
Daridorexant, Placebo - Liver Cirrhosis, Sleep Disturbance
Phase 4Not yet recruitingWang Fengmei1802026-12-012026-11-17
A Study of S-606001 as Monotherapy in Participants With Late-onset Pompe Disease (LOPD)
S-606001 - Pompe Disease
Phase 1Not yet recruitingShionogi152026-11-302026-11-17
An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)
S-606001, ERT - Pompe Disease
Phase 2Not yet recruitingShionogi602026-11-022026-10-13
Therapeutic Implications of CMR Low Native T1 in Non-treated Non-hypertrophic Females With Fabry Disease (FD)
Decision tree for initiating treatment - Fabry Disease
Not applicableNot yet recruitingUniversity Hospital, Bordeaux602026-11-012026-10-14
A First-in-Human Study of Phelimin in Healthy Volunteers and Adults With PKU
Phelimin - Phenylketonuria (PKU), Phenylketonuria
Phase 1Not yet recruitingMipSalus Aps72026-11-012026-11-10
Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)
Microbiota transplant therapy (MTT) capsules, Placebo capsule - Hepatic Encephalopathy, Cirrhosis
Phase 2Not yet recruitingVA Office of Research and Development1622026-10-302026-04-14

Showing 20 of 1525. Sign in to see all of them.

Narrower conditions

Fabry Disease (243)  ·  Hepatic Encephalopathy (218)  ·  Phenylketonurias (189)  ·  Gaucher Disease (176)  ·  Glycogen Storage Disease Type II (147)  ·  Hepatolenticular Degeneration (79)  ·  Fibrosis (73)  ·  Urea Cycle Disorders, Inborn (66)  ·  Adrenoleukodystrophy (63)  ·  Lysosomal Storage Diseases (63)  ·  Liver Cirrhosis (62)  ·  Ornithine Carbamoyltransferase Deficiency Disease (59)  ·  Metabolism, Inborn Errors (54)  ·  Leukodystrophy, Metachromatic (49)  ·  Rare Diseases (43)

Broader conditions

Nutritional and Metabolic Diseases (1520)  ·  Nervous System Diseases (1513)  ·  Central Nervous System Diseases (1512)  ·  Brain Diseases (1505)  ·  Metabolic Diseases (1490)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1294)  ·  Brain Diseases, Metabolic, Inborn (1269)  ·  Genetic Diseases, Inborn (1259)  ·  Metabolism, Inborn Errors (1229)  ·  Lysosomal Storage Diseases, Nervous System (709)  ·  Lysosomal Storage Diseases (649)  ·  Lipid Metabolism, Inborn Errors (565)  ·  Lipid Metabolism Disorders (563)  ·  Lipidoses (558)

Interventions

sapropterin (37)  ·  GAA protein, human (36)  ·  Lactulose (36)  ·  agalsidase beta (28)  ·  migalastat (28)  ·  Rifaximin (26)  ·  agalsidase alfa (24)  ·  Blood Specimen Collection (20)  ·  larazotide acetate (19)  ·  miglustat (18)  ·  pegvaliase (16)  ·  Glucosylceramidase (14)  ·  eliglustat (14)  ·  imiglucerase (14)  ·  glycerol phenylbutyrate (12)

Sponsors

Genzyme, a Sanofi Company (67)  ·  Amicus Therapeutics (38)  ·  BioMarin Pharmaceutical (38)  ·  Shire (34)  ·  Sanofi (28)  ·  Assistance Publique - Hôpitaux de Paris (23)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (19)  ·  CENTOGENE GmbH Rostock (18)  ·  Duke University (17)  ·  National Taiwan University Hospital (17)  ·  Amgen (14)  ·  Assiut University (14)  ·  National Center for Research Resources (NCRR) (14)  ·  Alexion Pharmaceuticals, Inc. (13)  ·  University of Minnesota (13)

Countries

United States (708)  ·  United Kingdom (228)  ·  France (194)  ·  Germany (168)  ·  Italy (139)  ·  Canada (129)  ·  Spain (119)  ·  China (101)  ·  Australia (86)  ·  Netherlands (75)  ·  Denmark (67)  ·  Belgium (58)  ·  Brazil (56)  ·  India (55)  ·  Israel (54)

Top investigators

Peter Bauer, Prof. (9)  ·  Anita MacDonald (8)  ·  Ozlem Goker-Alpan, MD (8)  ·  Paul Orchard, MD (7)  ·  Forbes D Porter, M.D. (6)  ·  Joanne Kurtzberg, MD (6)  ·  Michio Hirano, MD (5)

Results publications

PMID 37467180, PMID 24144944, PMID 27657681, PMID 19775921, PMID 21586746, PMID 22961727, PMID 27839979, PMID 32593547, PMID 33332761, PMID 36279795, PMID 37624739, PMID 39383458, PMID 39847314, PMID 40411344, PMID 40525490, PMID 41631150, PMID 20188616, PMID 20335583, PMID 21637107, PMID 23176611, PMID 23860343, PMID 23872605, PMID 25795794, PMID 26053270, PMID 27509102, PMID 27720916, PMID 28465125, PMID 28476546, PMID 28506905, PMID 31038755, PMID 31303277, PMID 31889231, PMID 32994552, PMID 33325055, PMID 33482890, PMID 34349180, PMID 34387740, PMID 34826353, PMID 35313729, PMID 36196048, PMID 36481125, PMID 36739645, PMID 38349709, PMID 39383459, PMID 39774103, PMID 40155993, PMID 40267426, PMID 40817303, PMID 41527340, PMID 41989430

NIH funding

2018 (11), 2019 (11), U54NS065768 (11), 2025 (8), 2015 (7), 2014 (6), 2008 (5), 2009 (5), 2023 (5), U54NS078059 (4), 2016 (3), 2017 (3), U54HD061221 (3), 2005 (2), P01HD032062 (2)